Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells 51,873 Shares of Stock

Posted by Geri Gentry on Apr 14th, 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the business’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $18.23, for a total transaction of $945,644.79. Following the transaction, the chief executive officer owned 2,924,893 shares of the company’s stock, valued at $53,320,799.39. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Da Silva Jorge Santos also recently made the following trade(s):

On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07.

MoonLake Immunotherapeutics Stock Up 1.9%

Shares of MoonLake Immunotherapeutics stock traded up $0.35 during trading on Tuesday, hitting $18.78. 1,079,418 shares of the stock were exchanged, compared to its average volume of 1,931,781. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27. The firm’s 50-day moving average price is $17.22 and its 200 day moving average price is $14.61. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -5.34 and a beta of 1.19. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, meeting the consensus estimate of ($0.92). During the same period in the previous year, the business posted ($0.72) earnings per share. As a group, analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth about $26,000. FNY Investment Advisers LLC acquired a new position in MoonLake Immunotherapeutics in the 3rd quarter valued at about $28,000. Bank of America Corp DE increased its position in MoonLake Immunotherapeutics by 64.7% in the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after acquiring an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after acquiring an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after acquiring an additional 1,069 shares during the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MLTX. HC Wainwright raised their target price on MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Needham & Company LLC upped their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Oppenheimer increased their price target on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and raised their price objective for the stock from $12.00 to $24.00 in a report on Monday, March 23rd. Finally, UBS Group set a $24.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $23.08.

Get Our Latest Stock Report on MoonLake Immunotherapeutics

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.